Tesamorelin (brand name Egrifta) is an FDA-approved drug for reducing visceral adiposity, particularly in HIV patients, and is taken about three times per week.

“the other what I'm calling type one growth hormone promoting peptide is tesamorelin this goes by the brand name grifta and it's an FDA approved drug for the reduction of visceral adiposity in HIV patients so we have subcutaneous fat and we have visceral fat around our organs visceral fat can be really problematic and for some people who have HIV or and for people who don't have HIV the deposits of visceral fat can be problematic for their health and tesamorelin again also called AG gria has been shown to reduce visceral adiposity it also seems to produce some of the other same effects that celin produces the differences between the two relate to small differences in the amino acid sequence for one peptide versus the other tesamorelin is a bit more long lasting than celin and therefore is taken typically about three times per week not five times per week”